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Abstract: This study aimed to examine whether inducible nitric oxide synthase (iNOS) plays 
a role in the delayed antiarrhythmic effect of sodium nitrite. Twenty-one dogs were infused 
intravenously with sodium nitrite (0.2 µmol/kg/min) for 20 min, either in the absence (n=12) 
or in the presence of the iNOS inhibitor S-(2-aminoethyl)-isothiourea (AEST; total dose: 2.0 
mg/kg; i.v., n=9). Control dogs (n=12) were given saline. Twenty-four hours later, all the 
dogs were subjected to a 25 min period occlusion of the left anterior descending (LAD) 
coronary artery, followed by rapid reperfusion. Dogs treated with AEST and nitrite were 
received again AEST prior to the occlusion. Compared to the controls, sodium nitrite 
markedly reduced the number of ectopic beats, the number and incidence of ventricular 
tachycardia and the incidence of ventricular fibrillation during occlusion and increased 
survival (0% vs. 50%) from the combined ischaemia and reperfusion insult. Although AEST 
completely inhibited iNOS activity, the nitrite induced increased NO bioavailability during 
occlusion was not substantially modified. Furthermore, AEST attenuated but did not 
completely abolish the antiarrhythmic effect of nitrite. The marked delayed antiarrhythmic 
effect of sodium nitrite is not entirely due to the activation of iNOS; other mechanisms may 
certainly play a role. 
 
Key words: arrhythmias, sodium nitrite, delayed protection, ischaemia/reperfusion, nitric 
oxide  
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Introduction  
There is experimental and clinical evidence that inorganic nitrite and nitrate, the natural 
products of nitric oxide (NO) metabolism, may serve as reservoirs of NO (Kevil and Lefer 
2011). This would be particularly important under ischaemic conditions, when in the absence 
of oxygen, the generation of NO from NOS enzyme activation is limited, and when the drop 
in pH and oxygen tension favours the reduction of nitrite to NO (Zweier et al. 1995), thus 
providing better cardiac function during ischaemia (Lefer 2006; Lundberg et al. 2011). 
Recently, we have shown that the intravenous infusion of sodium nitrite, in a concentration 
which does not significantly modify arterial blood pressure and coronary blood flow, 
profoundly reduced the severity of ventricular arrhythmias that resulted from a 25 min 
coronary artery occlusion and reperfusion in anaesthetized dogs (Kovács et al. 2015). This 
marked antiarrhythmic protection was associated with increased NO-mediated reduction in 
oxidative stress, perhaps through protein S-nitrosylation and/or S-glutathionylation (Kovács et 
al. 2015). 
We have a number of evidence that in this dog model, preconditioning induced by various  
mechanical (coronary artery occlusion, cardiac pacing, exercise; Babai et al. 2000; Kis et al. 
1999a,b; Végh et al. 1992a, 1994) and pharmacological stimuli (NO donors, statins; György 
et al. 2000; Kisvári et al. 2014), results in marked early and delayed antiarrhythmic effect 
(György et al. 2000; Végh et al. 1992a), and that this protection is associated with the 
maintenance of NO availability during ischaemia (Kiss et al. 2010). The importance of NO, 
both in the early and the delayed cardioprotection is well established (Bolli et al. 1997; Végh 
et al. 1992b; Végh and Parratt 1996). For example, we know that in the delayed effect, NO, 
generated by the preconditioning stimulus via the rapid activation of the endothelial nitric 
oxide synthase (eNOS), stimulates further NO synthesis by activating the inducible form of 
NOS (iNOS; Bolli et al. 1997), and perhaps eNOS as well (Kovács et al. 2013). This 
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mechanism is certainly involved in the late antiarrhythmic effect, since the inhibition of iNOS 
activation attenuates or even abolishes the protection (Hajnal et al. 2005; Kis et al. 1999a,b; 
Végh et al. 1994).  
There is also some evidence that sodium nitrite induces delayed protective effects in various 
experimental models (Shiva et al. 2007b). However, it is unknown, whether it can evoke 
delayed protection against arrhythmias, and if so, what mechanisms would play a role. It has 
been proposed that nitrite causes early mitochondrial S-nitrosylation, which is stable for 24h, 
and protects mitochondrial function, when the heart is subjected to ischaemia (Shiva et al. 
1997a,b). Although this mechanism seems to be very likely, we have now examined, whether 
iNOS, would also be involved in the delayed effect of nitrite. Therefore, we used S-(2-
aminoethyl)-isothiourea (AEST), a relatively selective inhibitor of iNOS. The changes in the 
severity of ischaemia and arrhythmias, in iNOS activity and in the plasma nitrate/nitrite levels 
were examined during the experiments. 
Materials and methods 
Ethics 
The upkeep of the dogs was in accordance with the Hungarian law (XVIII/VI/31) regarding 
large experimental animals, which conforms to the Guide for the Care and Use of Laboratory 
Animals by the US National Institutes of Health (NIH publication No.85-23, revised in 1996), 
and conformed to the European Parliament Directive 2010/63/EU. All animal experiments 
were supervised and approved by the Department of Animal Health and Food Control of the 
Ministry of Agriculture and Rural Development (No.XIII/1211/2012) and the Ethical 
Committee for the Protection of Animals in Research of University of Szeged, Szeged, 
Hungary (No.I-74-5-2012). 
Surgical procedures 
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Thirty-three adult mongrel dogs of either sex, with a mean body weight of 21 ± 4 kg were 
used. The dogs were housed in a separated animal room (temperature: 10–20°C, humidity: 
40–70%, lightening: 12 h per day, 2 animals per pen) for two weeks and fed a standard diet 
and ad libitum access to water. Food was withdrawn 24 h before anesthesia. 
On the first day the dogs were lightly anaesthetized with sodium pentobarbitone (30 mg/kg; 
Euthasol 40% i.v. A.U.V., Produlab Pharma B.V., Raamsdonksveer, The Netherlands). A 
polyethylene catheter was introduced into the jugular vein through which the drugs (sodium 
nitrite, AEST, saline) were administered intravenously. A Millar tip catheter ((5F, Millar 
Instruments Inc., Houston, TX, USA) was positioned into the left carotid artery for 
monitoring changes in arterial blood pressure.  
On the second day, the dogs were re-anaesthetized with a bolus injection of sodium 
pentobarbitone (30 mg/kg, iv.), and the anesthesia was maintained with intravenous injections 
of a mixture of chloralose and urethane (60 and 200 mg/kg respectively; Sigma, St. Louis, 
MO, USA). The depth of anaesthesia was monitored by the examination of the cornea and 
pain reflexes as well as by the measurement of blood pressure, and when it was necessary, a 
further bolus injection of the anaesthetic was given. The dogs were ventilated with room air 
using a Harvard respirator (Harvard Apparatus, Natick, MA, USA) at a rate and volume 
sufficient to maintain arterial blood gases within normal limits (Végh et al. 1992). Body 
temperature was measured from the mid-oesophagus and maintained at 37 ± 0.5 oC.  
A catheter (Cordis F4) was introduced into the right femoral artery to measure arterial blood 
pressure (systolic and diastolic). The Millar tip catheter (5F, Millar Instruments Inc., Houston, 
TX, USA), which had been introduced into the left carotid artery on day one, was now pushed 
into the left ventricle (LV) for measuring LV systolic and end-diastolic pressure as well as 
and LV positive and negative dP/dtmax. Through the right jugular vein, another catheter was 
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positioned into the coronary sinus to obtain blood samples for the measurement of plasma 
nitrate/nitrite (NOx) levels. 
A thoracotomy was performed at the fifth intercostal space, the pericardium was transected 
and the heart was explored. The descending branch of the left coronary artery (LAD) was 
prepared for occlusion proximal to the first main diagonal branch.  
The severity of myocardial ischaemia was assessed by the measurement of changes in the 
degree of electrical activation and in epicardial ST-segment using a composite electrode 
positioned within the potential ischaemic region as described in detail previously (Végh et al. 
1992a). The composite electrode collects R waves from 28 epicardial points with a bipolar 
lead, and the degree of inhomogeneity of electrical activation is assessed as a time delay 
between the first and a last point activated under the electrode, and expressed in milliseconds. 
The electrode also contains 4 unipolar electrodes by which changes in epicardial ST-segment 
(in mV) are assessed. A chest lead II standard electrocardiogram (Plugsys Hemodynamic 
Apparatus; Hugo Sachs Electronik, March-Hugstetten, Germany) was also recorded to 
measure heart rate (HR) and assess the number and severity of arrhythmias.  
Ventricular arrhythmias were evaluated according to the Lambeth Conventions (Walker et al. 
1998) with a modification as previously outlined (Végh et al. 1992a). Thus, the total number 
of ventricular premature beats (VPBs), the incidence and the number of episodes of 
ventricular tachycardia (VT), and the incidence of ventricular fibrillation (VF) were assessed 
during the occlusion period. During reperfusion, only the incidence of VF (which is a final 
event in this species) was determined. Dogs that were still alive 2 min after reperfusion (the 
end of the study) were considered to be survivors. Those dogs that survived reperfusion were 
euthanized by an excess dose of the anaesthetic. All recordings were assembled and evaluated 
by LabChart 7 (AD Instruments Pty Ltd, Bella Vista, Australia) software. 
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Determination of iNOS activity 
This was performed using the radio immunoassay method. The preparation of the myocardial 
tissue samples (200 mg) were identical as described previously (Kisvári et al. 2014). Total 
protein concentrations were determined by the method of Bradford. 
The measurements were carried out in the absence of calcium and calmodulin using NOS 
activity assay kit (Cayman Chemical, Ann Arbor, MI, USA), based on the conversion of [3H] 
L-arginine to [3H] L-citrulline by NOS. To eliminate background NOS activity in control 
samples, 10 mmol L-NG-Nitro-arginine (L-NNA), a non-specific inhibitor of the NOS enzyme 
was given to the reaction mixture before the addition of the tissue extract. A liquid 
scintillation counter (Wizard TM, PerkinElmer, Waltham, MA, USA) was used to detect the 
amount of radiolabeled L-citrulline formed during the reaction by iNOS, and expressed as the 
percentage of the total counts corrected with the background counts per minute.  
Assessment of plasma nitrite/nitrate (NOx) levels 
This was determined by Griess reaction as described previously (Kiss et al. 2010; Kisvári et 
al. 2014). Plasma samples were collected from the jugular vein (day one) and after 
thoracotomy (day two) from the coronary sinus at different time points as indicated in Figure 
1). The absorbance of the azo-compound was measured spectrophotometrically at 540 nm 
using a microplate reader (FLUOstar OPTIMA, BMG LABTECH GmbH, Ortenberg, 
Germany). The total nitrate/nitrite (NOx) concentration (µmol/l) was determined using a 
standard calibration curve of NaNO2 and NaNO3 (Sigma, St Louis, MO, USA).  Data were 
analyzed by OPTIMA (Control and Data Analyses; BMG LABTECH GmbH, Ortenberg, 
Germany) software.  
Experimental protocol 
A total number of 33 dogs were used and randomly divided into three groups. On day one the 
dogs were slightly anaesthetized and infused intravenously either with saline (control group; n 
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= 12) or sodium nitrite (NaNO2 group; n = 21; 0.2 µmol/kg/min) for 20 minutes (Figure 1). 
Twenty-four hours later all the dogs were subjected to a 25 min occlusion of the anterior 
descending branch of the left coronary artery (LAD), followed by rapid reperfusion. In 9 dogs 
out of the sodium nitrite treated dogs, S-(2-aminoethyl)-isothiourea (AEST+NaNO2 group) 
was slowly injected (over 5 min) intravenously in a total dose of 2 mg/kg, 5 min before the 
commencement of the sodium nitrite infusion. In these dogs, 24 h later, the same dose of 
AEST was given again in intravenous infusion for 30 min, just prior to the coronary artery 
occlusion. The dose of AEST applied in the present study was identical that of used 
previously to inhibit iNOS activity (Kis et al. 1999). Since in that study we have proved that 
AEST given to control dogs (subjected only to ischaemia and reperfusion) does not modify 
arrhythmia severity (Kis et al. 1999), therefore in this work we did not include a separate 
AEST control group. Three dogs served as sham-operated (SO) controls (not included in the 
protocol figure); from these animals myocardial tissue samples were collected in order to 
determine iNOS activity in healthy myocardium. 
At the end of the experiments the dogs were euthanized by an excess of the anaesthetic, and 
myocardial tissue samples (TS) were collected either 2 min after reperfusion (these animals 
were considered as survivors) or at the time when the fibrillation was observed for further 
analyses (Figure 1). Blood samples (BS) were also collected at different time points as 
indicated on the figure (Figure 1). In some dogs (at least 5 dogs in each group), the size of the 
area, affected by the occlusion, was assessed using the same method that has been described 
in detail previously (Végh et al. 1992a). In brief, at the end of the experiments the heart was 
removed, and Patent Blue V dye was infused into the re-occluded LAD artery, whereas saline 
was infused into the patent left circumflex (LCX) artery, at a pressure equivalent to that of 
mean arterial pressure. The dyed area was cut out and weighed, and the area at risk was 
expressed as a percentage of the left ventricular wall, together with the septum. 
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Statistical analysis 
The data were expressed as mean ± SEM, and differences between means were compared by 
ANOVA for repeated measures and by one-way ANOVA as appropriate, using the Fisher 
post hoc and Bonferroni tests. The number of VPBs and the number of episodes of VT were 
compared using the Kruskal-Wallis test. The incidence of VT and VF, as well as survival 
from the combined ischaemia and reperfusion insult was compared by the Fisher Exact test. 
Differences between groups were considered significant at P<0.05.  
Results 
Haemodynamic effects of intravenously administered saline, sodium nitrite and AEST  
These are illustrated in Table 1. Compared to the saline treated controls, the intravenous 
infusion of sodium nitrite resulted in significant reductions in arterial blood pressure and a 
slight increase in heart rate. AEST itself had no significant effect on any haemodynamic 
parameters, measured either on day one, i.e. prior to the infusion of sodium nitrite, or day two, 
i.e. just prior to the occlusion, but significantly attenuated the haemodynamic effects of the 
intravenously administered sodium nitrite.     
Haemodynamic changes following coronary artery occlusion 
These are shown in Table 2. In all groups, occlusion of the LAD resulted in significant 
reductions in arterial blood pressure, LVSP, positive and negative dP/dtmax and an increase in 
LVEDP, whereas the HR remained substantially unchanged. These haemodynamic alterations 
were somewhat less pronounced in dogs given sodium nitrite, 24h previously. The 
administration of AEST in the nitrite treated dogs did not substantially modify the occlusion-
induced haemodynamic changes compared either to the controls or the nitrite treated dogs.  
The severity of arrhythmias during coronary artery occlusion and reperfusion 
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The number and the incidence of various types of arrhythmias, occurring during a 25 min 
occlusion are illustrated in Figure 2. In control dogs, there were a high numbers of VPBs and 
episodes of VT that were apparent in all the examined dogs. Furthermore, in 5 dogs out of the 
12 (42%) control animals, VF occurred during the occlusion period and the rest of the dogs 
fibrillated on reperfusion, thus no dog in this group survived the combined ischaemia and 
reperfusion insult. In contrast, dogs infused with sodium nitrite 24h previously, exhibited only 
few ectopic beats and episodes of VT, which occurred in 2 of the 9 (22%) nitrite treated dogs. 
Furthermore, in this group no dog fibrillated during occlusion and 50% of the animals 
survived reperfusion (Figure 2). When AEST was given both prior to the infusion of nitrite 
(on day one) and, 24h later, just before the occlusion, the number of ectopic beats and the 
episodes of VT, as well as the incidence of VT during occlusion were again increased,  but 
remained still significantly less than in the untreated controls. Inhibition of iNOS with AEST 
did not significantly modify the protective effect of nitrite on the incidence of ischaemia-
induced VF; i.e. in the presence of AEST only 1 nitrite treated dog out of the 9 dogs (11 %) 
fibrillated during occlusion. AEST, however, abolished the protective effect of nitrite on the 
reperfusion-induced VF. In the AEST-NaNO2 group only one dog (11%) survived the 
combined ischaemia and reperfusion insult. 
The severity of ischaemia during coronary artery occlusion 
This was assessed by measuring changes in epicardial ST-segment and in the degree of 
inhomogeneity of electrical activation (Figure 3). In control dogs, both the epicardial ST-
segment (Figure 3A) and the degree of inhomogeneity of electrical activation (Figure 3B) 
were rapidly elevated during the first 5 min of the occlusion, and reached a maximum value of 
around 11 mV and 130 ms, respectively, at the 5 min of ischaemia. The administration of 
sodium nitrite, 24 h previously, significantly suppressed these ischaemic changes; both the 
development and the absolute values of the elevation of the epicardial ST-segment and of the 
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degree of inhomogeneity were much slower and less than in the controls. The administration 
of AEST almost completely abolished the anti-ischaemic effects of sodium nitrite.  
Changes in plasma nitrate/nitrite (NOx) levels 
These were determined both before and after the intravenous administration of sodium nitrite 
from the venous blood and also 24h later, before and after the occlusion of the LAD in blood 
samples taken from the coronary sinus, as shown in the protocol figure (Figure 1). In control 
dogs infused with saline intravenously, there were no significant differences between the 
baseline (pre-infusion) and the 20 min values of nitrate and nitrite levels. In contrast, the 
infusion of sodium nitrite significantly increased the plasma nitrate and nitrite, as well as NOx 
concentrations irrespective whether AEST was present or not (Figure 4).  
Whereas on day one there were no significant differences between the baseline values of NO 
metabolites among the groups, on day two a marked difference occurred between the control 
and nitrite treated dogs in the NOx levels, measured just prior to the occlusion in the blood of 
the coronary sinus. Thus both in the nitrite and the AEST+NaNO2 groups, there was a 
significant increase in the NOx levels that resulted primarily from the marked elevation in the 
nitrate levels, since the nitrite concentrations were almost the same in all groups as the day 
one baseline values. This result indicates that sodium nitrite, under oxygenated conditions, 
occurred as nitrate in the blood, 24h later.  
When the LAD coronary artery was occluded, in the control dogs both the nitrate and nitrite 
levels were significantly reduced, resulting in a marked decrease in NOx by the end of the 
occlusion period. Compared to these changes, in the nitrite treated dogs the nitrate 
concentrations were considerable decreased and the nitrite concentrations increased during 
coronary artery occlusion, suggesting a possibility for non-enzymatic NO formation under 
reductive conditions. Since, in these dogs the reduction in the nitrate concentrations was more 
marked than the increase in nitrite concentrations, the NOx levels showed also a decrease 
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during the occlusion. Nevertheless, the NO bioavailability in the nitrite infused dogs was 
significantly higher during ischaemia than in the saline infused controls. The administration of 
AEST did not significantly modify the nitrite-induced changes in the level of NO metabolites.            
The effect of nitrite on iNOS activity 
This is illustrated in Figure 5. Compared to the sham operated controls, in samples taken from 
dogs subjected only to a 25 min occlusion and reperfusion insult, no significant changes could 
be observed in the activation of iNOS. The administration of nitrite resulted in a slight 
increase in iNOS activation, which was completely abolished by the administration of AEST.  
Area at risk  
There were no significant differences in the area at risk among the groups. Thus the risk area 
was 36 ± 3% in the controls, 37 ± 3% in the sodium nitrite, and 35 ± 4% in the AEST + 
NaNO2 treated groups. 
Discussion 
The aim of the present study was to test the hypothesis in our canine model of ischaemia and 
reperfusion, whether the administration of sodium nitrite can produce delayed antiarrhythmic 
effect, and if so, whether this effect, similar to preconditioning, involves the activation of 
iNOS. This question was raised, because there is evidence, albeit in different models, that 
sodium nitrite evokes delayed cardioprotection (Shiva et al. 2007b; Shiva and Gladwin 2009), 
but the mechanism by which this protection attains, is not well understood. We do not know, 
whether nitrite itself, or after converting to NO would elicit the protection. It is also not clear, 
how this conversion will take place under physiological conditions? To give answers, at least 
a part of these questions, first we designed studies to examine the possibility, whether the 
activation of iNOS plays a role in the nitrite-induced delayed antiarrhythmic protection.  
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This hypothesis was based on those previous findings which clearly showed that iNOS has a 
crucial role in the delayed cardioprotective effects of preconditioning (Bolli et al. 1997; Végh 
and Parratt 1996). It was proposed that the preconditioning stimulus, via the activation of 
eNOS, enhances the formation of NO, which is then stimulates iNOS (and most probably 
eNOS as well; Kovács et al. 2013), resulting in further NO generation (Bolli et al. 1997). This 
iNOS derived enhanced NO production certainly contributes to the protection 24h later, when 
the hearts are subjected to an ischaemia and reperfusion challenge (Bolli et al. 1997; Végh et 
al. 1994). The evidence for this NO-induced NO formation via the activation of NOS enzyme 
isoforms, comes from the direct measurement of enzyme activity (Bolli et al. 1997; Kovács et 
al. 2013) and from the use of the relatively selective inhibitors of iNOS, such as 
aminoguanidine (Kis et al. 1999a) or S-(2-aminoethyl)-isothiourea (Hajnal et al. 2005; Kis et 
al. 1999b). However, as to whether sodium nitrite, infused 24h prior to an 
ischaemia/reperfusion insult, uses the similar pathway to induce protection is not known, and 
to our best knowledge it has not yet been investigated. 
We have found that sodium nitrite administered in dogs 24h before coronary artery occlusion 
and reperfusion results in significant antiarrhythmic effect. Thus the number and incidence of 
the various types of arrhythmias, resulting from a 25 min occlusion and then reperfusion of 
the LAD, were markedly reduced compared with the untreated controls. Similarly, the 
infusion of nitrite significantly attenuated the ischaemic changes, assessed by measuring 
epicardial ST-segment and the degree of inhomogeneity of electrical activation. We have also 
found that AEST, given twice in dogs infused with sodium nitrite, only partially, but not 
completely abolished the protective effects of nitrite against arrhythmias. Thus in the presence 
of AEST there was an increase in the number of ectopic beats and of episodes of VT during 
occlusion, but these were still significantly less than in the controls (Figure 2). Furthermore, 
AEST did not substantially modify the protective effect of nitrite against the occlusion-
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induced VF, but it abolished the protection against the reperfusion-induced VF. AEST also 
reversed the anti-ischaemic effects of nitrite (Figure 3). Thus we may conclude that the 
activation of iNOS might have a role in the delayed antiarrhythmic effect of sodium nitrite.  
This conclusion is supported by the results obtained from the measurement of iNOS activity. 
These show that sodium nitrite increased (although it was statistically not significant) the 
activity of iNOS. This increase was completely abolished in the presence of AEST; moreover, 
in the AEST treated dogs the iNOS activity was somewhat lower than in the sham-operated 
controls. This result confirms the findings of our previous studies that AEST is able to 
effectively block the activation of iNOS, and subsequently the iNOS-derived generation of 
NO, to which we attribute a key role in the delayed cardioprotection (Kis et al. 1999b; Végh 
et al. 1994). However, whereas AEST completely blocked the delayed antiarrhythmic effect 
of the preconditioning stimuli, such as cardiac pacing (Kis et al. 1999b) and treadmill exercise 
(Hajnal et al. 2005), it only attenuated the nitrite-induced late antiarrhythmic effect. This 
finding raises the possibility that, in some aspects, there might be a difference between the 
preconditioning and the sodium nitrite-induced protection, as regards the source of NO during 
ischaemia. Whereas in the preconditioning-induced delayed protection the iNOS-induced NO 
generation seems to have a mandatory role (Bolli et al. 1997; Dawn and Bolli 2002; Végh and 
Parratt 1996), since the inhibition of iNOS activation abolishes the protection (Kis et al. 
1999a,b; Végh et al. 1994), in case of the nitrite evoked delayed protection the activation of 
iNOS to produce NO is probably less important, since after the complete inhibition of iNOS 
activity, the protection, at least against the occlusion-induced arrhythmias, is still present. 
In order to examine the source of NO 24h after the administration of sodium nitrite, we 
measured plasma nitrate and nitrite levels twice; i.e. on day one before and after the 20 min 
infusion of nitrite in the systemic blood, and also on day two, before and after a 25 min 
coronary artery occlusion in the blood of the coronary sinus. We have found that there were 
Page 14 of 31
Ca
n.
 J.
 P
hy
sio
l. 
Ph
ar
m
ac
ol
. D
ow
nl
oa
de
d 
fro
m
 w
w
w
.n
rc
re
se
ar
ch
pr
es
s.c
om
 b
y 
U
ni
ve
rs
ité
 d
e 
Sh
er
br
oo
ke
 o
n 
12
/0
8/
16
Fo
r p
er
so
na
l u
se
 o
nl
y.
 T
hi
s J
us
t-I
N
 m
an
us
cr
ip
t i
s t
he
 a
cc
ep
te
d 
m
an
us
cr
ip
t p
rio
r t
o 
co
py
 e
di
tin
g 
an
d 
pa
ge
 c
om
po
sit
io
n.
 It
 m
ay
 d
iff
er
 fr
om
 th
e 
fin
al
 o
ffi
ci
al
 v
er
sio
n 
of
 re
co
rd
. 
 15
no significant differences among the groups in the baseline (pre-infusion) nitrate, nitrite and 
NOx levels. However, in dogs infused with nitrite, irrespective of the presence of AEST, the 
concentration of NO metabolites were markedly increased by the end of the infusion period 
compared with the saline infused controls (Figure 4). Twenty four hours later, when the level 
of these NO metabolites had been assessed again, now in the blood of the coronary sinus, we 
observed that in all groups the nitrite levels were almost the same as the basal plasma nitrite 
concentrations, 24h previously (Figure 4). In contrast, the nitrate concentrations were highly 
elevated in the nitrite treated dogs compared with the controls. We think that by this time 
nitrite has converted to nitrate, and in the absence of food intake, the nitrate levels were only 
affected by the renal function over the 24h observation period (Lauer et al. 2001). At this 
time, if the dogs had been subjected to coronary artery occlusion, the total nitrate/nitrite 
(NOx) concentrations were reduced in all groups compared to their corresponding pre-
occlusion values, but in the nitrite treated dogs, NOx was significantly higher than in the 
untreated controls (Figure 4). Furthermore, the reduction in NOx of the nitrite infused animals 
resulted mainly from the marked decrease in nitrate concentrations, whereas the nitrite levels 
were rather increased, indicating that nitrate reduced to nitrite, and then possible to NO during 
occlusion. In contrast, in the control dogs the marked reduction in NOx, determined at the end 
of the occlusion period, resulted from a significant decrease in both the nitrate and nitrite 
concentrations (Figure 4).  
What conclusions we may draw from these results? First, it seems that following nitrite 
administration, the majority of nitrite is converted to nitrate, and it remains and circulates in 
this form over the next 24h period. We may speculate that even under normal, oxygenated 
conditions, a part of the infused nitrite may convert to NO, which reductive process largely 
depends on the nitrite reductase activity of deoxy-haemoglobin (Hb) and xanthine 
oxidoreductase (Dejam et al. 2004). We also know that the activity of these nitrite reductive 
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mechanisms increases with decreasing pO2, and pH, and with increasing NAD+ concentration, 
which milieu is rather unusual under physiologic conditions (Dejam et al. 2004). Therefore, in 
the absence of direct measurement of NO formation and/or of nitrite reductase activity, we are 
not able to provide evidence for the existence of such a nitrite to NO conversion in our 
experiments, but of course, the possibility of this mechanism cannot be excluded. The 
possible operation of these abovementioned nitrite reductase mechanisms (Lauer et al. 2001) 
in our experiments is supported by the fact that we have found an increase in iNOS activity 
24h after nitrite administration, which almost certainly resulted from the enzyme stimulation 
by NO (Figure 5). This enzyme activation was completely abolished in the presence of AEST.  
Second, our results show that under ischaemic conditions the heart of the nitrite treated dogs 
uses nitrate as a primary source for NO production via its reduction to nitrite and then to NO. 
This non-enzymatic NO formation provides adequate amount of NO during occlusion and the 
subsequent reperfusion to elicit protection against the ischaemic changes and arrhythmias. 
The fact that a part of the protection, such as against the ischaemia-induced ventricular 
arrhythmias, has still remained in the presence of AEST, further that the complete inhibition 
of the activity of iNOS did not modify the nitrite-induced effects on the concentration of NO 
metabolites suggest that iNOS, and the iNOS derived NO has only a minor role in the nitrite-
evoked delayed antiarrhythmic protection during ischaemia. On the other hand, the fact that 
AEST markedly attenuated the nitrite-induced protection against the ischaemic changes and 
the reperfusion-induced severe ventricular arrhythmias suggests a role for iNOS-derived NO 
in the protective effect of nitrite. We suppose that this enzymatic NO formation becomes 
particularly important during reoxygenation, when the rapid change in the milieu stops the 
nitrate-nitrite-NO conversion that has provided NO during ischaemia. Thus under these 
conditions the blockade of the additional NO source (iNOS) would result in the abolition of 
the nitrite-induced protection.   
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The first evidence that inorganic nitrites may provide delayed protection resulted from studies 
of Shiva and his colleagues (Shiva et al. 2007a,b; Shiva and Gladwin 2009). They showed in 
various in vitro and in vivo models that nitrite administered 24h prior to ischaemia produces 
similar protection by the same mechanism as nitrite given acutely (Shiva and Gladwin 2009). 
They proposed that nitrite through S-nitrosylation of mitochondrial proteins, particularly 
complex I, mediates both the early and delayed protection (Shiva et al. 2007b). It was 
suggested that mitochondrial S-nitrosylation occurs rapidly following the administration of 
nitrite and it remains stable for 24h (Shiva and Gladwin 2009). The role of S-nitrosylation as a 
potential mechanism in the acute effect of nitrite has been confirmed in our own studies as 
well. We have shown that when sodium nitrite was administered either prior to and during the 
occlusion, or just prior to reperfusion, provided a marked antiarrhythmic protection against 
the ischaemia and reperfusion-induced severe ventricular arrhythmias and this effect was 
associated with protein S-nitrosylation and glutathionylation (Kovács et al. 2015). Although 
the role of stable protein S-nitrosylation cannot be ruled out as one of the potential 
mechanisms for the explanation of the delayed cardioprotection resulted from nitrite 
administration (Shiva et al. 2007b), there is a lack of sufficient information how this 
prolonged protein S-nitrosylation would take place. The results of studies in vitro from the 
same group (Shiva et al. 2007a) suggest that deoxymyoglobin, which nitrite reductase activity 
is much higher than deoxyhemoglobin to reduce nitrite, would be the candidate for conserving 
and generating NO via nitrite reduction under physiological conditions (Shiva et al. 2007a). 
Although in the present study we did not assess protein S-nitrosylation, we are not fully 
convinced that same mechanism operates under in vivo conditions and fully explains the 
marked delayed antiarrhythmic effect of sodium nitrite. What we can propose as an 
alternative and/or additional hypothesis for the delayed protective effect of nitrite that results 
from the nitrite/nitrate measurements in our large animal experiments, is that under 
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physiological conditions the majority of the infused nitrite converts to nitrate, and in this form 
is stored over the next 24h. This is supported by the fact that the nitrate, but not the nitrite 
levels were markedly increased 24h after the infusion of nitrite. As to whether mitochondrial 
protein S-nitrosylation would take place before the conversion of nitrite to nitrate we do not 
know yet, but the possibility of such a mechanism cannot be excluded. This warrants further 
examination in our model. The results of the measurement of iNOS activity, however, suggest 
that a part of nitrite is most probably converted to NO, and this was sufficient to stimulate 
iNOS. The fact that AEST, although completely blocked the activity of iNOS, it did not 
modify the concentration of NO metabolites and the occlusion-induced arrhythmias suggests 
that iNOS has only a minor contribution to NO formation and the protection in the nitrite 
treated dogs. We propose that dogs treated with nitrite, use nitrate as a primary source of NO 
during ischaemia. This is converted back first to nitrite and then to NO, when reductive 
conditions attains, such as during coronary artery occlusion, when we could observed a 
marked reduction in the nitrate, and an increase in the nitrite concentrations.  
In conclusion, the results of the present study provided evidence that, in contrast with 
preconditioning, the activation of iNOS does not play a mandatory role in the nitrite-induced 
delayed antiarrhythmic protection, since the blockade of iNOS activation only attenuated but 
not completely abolished the protection. To explore mechanisms, which may contribute to the 
marked delayed antiarrhythmic effect of sodium nitrite, warrants further investigations which 
are in progress. 
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Table 1. Haemodynamic effects of saline, sodium nitrite and sodium nitrite and S-(2-aminoethyl)-isothiourea (AEST) 
 Saline NaNO2 AEST§ AEST + NaNO2 
     Day 1 Day 2   
 Baseline Max change Baseline Max change Baseline Max change Baseline Max change Baseline Max change 
SABP (mmHg) 148 ± 6 3 ± 2 155 ± 6  -11 ± 4* 161 ± 5     -1 ± 4 142 ± 4 5 ± 6* 153 ± 3     -3 ± 3† 
DABP (mmHg) 100 ± 6 3 ± 2 122 ± 4    -7 ± 2*# 129 ± 4 -4 ± 2*# 101 ± 5 5 ± 6* 117 ± 3 -2 ± 2#† 
MABP (mmHg) 116 ± 6 3 ± 2 133 ± 5    -8 ± 3* 140 ± 4 -3 ± 2*# 115 ± 4 4 ± 6* 136 ± 3 -3 ± 2#† 
HR (beats/min) 159 ± 5 3 ± 1 166 ± 6     6 ± 2*# 187 ± 7 -13 ± 3*# 166 ± 2 -2 ± 2* 173 ± 4 -3 ± 3#† 
 
Values are mean ± SEM, calculated from n=8 experiments.*P<0.05 vs. baseline value, #P<0.05 vs. control group, †P<0.05 vs. NaNO2 
group. Abbreviations: SABP: systolic arterial blood pressure, DABP: diastolic arterial blood pressure, MABP: mean arterial blood pressure,  
HR: heart rate. AEST§: These data represent the acute haemodynamic effects of AEST, when it was given before the administration of 
sodium nitrite (day 1), and 24h later (day 2), when it was infused for 30 min prior to occlusion in the nitrite treated dogs.    
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Table 2. Haemodynamic changes during a 25 min occlusion of the LAD 
 Saline NaNO2 AEST+ NaNO2 
 Baseline Max change Baseline Max change Baseline Max change 
SABP (mmHg) 140 ± 13 -17 ± 3* 146 ± 5 -11 ± 4* 146 ± 8 -14 ± 3* 
DABP (mmHg) 99 ± 9 -18 ± 3*  98 ± 4  -11 ± 5* 105 ± 6 -12 ± 3* 
MABP (mmHg) 113 ± 10 -17 ± 2* 114 ± 4  -11 ± 3* 119 ± 7 -13 ± 4* 
LVSP (mmHg) 141 ± 9  -19 ± 5*   148 ± 12 -10 ± 5* 146 ± 9 -16 ± 2* 
LVEDP (mmHg) 6.0 ± 1.1     7.3 ± 1.3*     3.0 ± 0.4      5.3 ± 0.6*#   2.7 ± 0.3    6.4 ± 0.6* 
+dP/dtmax (mmHg/s) 2792 ± 210 -720 ± 84*   2906 ± 136   -535 ± 130*  3431 ± 114   -710 ± 130* 
-dP/dtmax (mmHg/s) 2526 ±164    -583 ± 167*  2347 ± 75     -166 ± 112*#  2523 ± 149 -535 ± 62* 
HR (beats/min) 167 ± 6 4 ± 4  161 ± 8 -4 ± 2  161 ± 4  4 ± 2 
 
Values are mean ± SEM, calculated from n=8 experiments.*P<0.05 vs. baseline value, #P<0.05 vs. saline treated control group. 
Abbreviations: SABP: systolic arterial blood pressure, DABP: diastolic arterial blood pressure, MABP: mean arterial blood 
pressure, LVSP: left ventricular systolic pressure, LVEDP: left ventricular end-diastolic pressure, HR: heart rate.  
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Figure legends 
Figure 1. Experimental protocol. Three groups of dogs were used. On day one, control dogs 
(n = 12) were received saline in intravenous infusion over a 20 min period. In 21 dogs sodium 
nitrite was infused in a dose of 0.2 µmol/kg/min) for 20 minutes, either in the absence 
(NaNO2 group; n = 12) or in the presence of the iNOS inhibitor S-(2-aminoethyl)-isothiourea 
(AEST+NaNO2 group; n = 9). AEST was slowly injected (over 5 min) intravenously, in a 
total dose of 2 mg/kg 5 min before the commencement of the sodium nitrite infusion. Twenty-
four hours later (day 2), all the dogs were subjected to a 25 min occlusion of the anterior 
descending branch of the left coronary artery (LAD), followed by rapid reperfusion. In the 
AEST+NaNO2 group, AEST was given again in intravenous infusion for 30 min, just prior to 
the coronary artery occlusion. During the experiments blood samples (BS) were taken from 
the jugular vein before (0 min) and after (20 min) nitrite administration, as well as 24h later 
from the coronary sinus in order to determine changes in nitrate/nitrite levels before (0 min), 
and during (7, 12, 17, 25 min) coronary artery occlusion, as well as immediately (1 min) 
following reperfusion. Myocardial tissue samples (TS) were collected either 2 min after 
reperfusion (these animals were considered as survivors) or at the time when the fibrillation 
was observed for further biochemical analyses. 
Figure 2. The number and incidence of ventricular arrhythmias during a 25 min occlusion and 
reperfusion of the LAD in control, in sodium nitrite treated dogs (NaNO2), and in dogs that 
infused with nitrite in the presence of AEST (AEST + NaNO2). Compared to the controls, 
nitrite significantly reduced the number and incidence of ventricular arrhythmias during 
occlusion and increased survival on reperfusion. AEST partially reversed the antiarrhythmic 
effect of nitrite during occlusion, but it abolished the protection against the reperfusion-
induced arrhythmias. Values are means ± S.E.M. *P < 0.05 compared to the controls, #P < 
0.05 compared to the nitrite-treated dogs.  
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Figure 3. Changes in the epicardial ST-segment (A) and in the degree of inhomogeneity of 
electrical activation (B) during a 25 min occlusion of the LAD. Compared with controls, 
sodium nitrite significantly attenuated both indices of ischaemia severity. These effects of 
nitrite were markedly attenuated in the presence of AEST. Values are means ± S.E.M. *P < 
0.05 compared to the controls. 
Figure  4. Changes in nitrite (NO2), nitrate (NO3) and NOx plasma levels, determined in the 
venous blood before and after the administration of sodium nitrite, and also 24h later, in the 
blood of the coronary sinus, before and after the occlusion of the LAD. Compared to the pre-
infusion values, the infusion of nitrite elevated the nitrite and nitrate levels, irrespective 
whether AEST was present or not. Twenty-four hours later, the nitrite concentrations in all 
groups were similar to the normal, initial values, whereas the nitrate levels were markedly 
elevated in the nitrite treated dogs. Occlusion of the LAD significantly reduced NOx in all 
groups, but the level of NO metabolites in the nitrite treated dogs were significantly higher 
than in the controls. These changes were also independent from the presence of AEST. Values 
are means ± S.E.M. *P < 0.05 compared to the pre-infusion (baseline) value of the 
corresponding group, #P < 0.05 compared to the pre-occlusion value of the corresponding 
group, and †P < 0.05 compared to the control group.  
Figure 5. Changes in iNOS enzyme activity, determined by radioimmunoassay, in the sham-
operated control (n = 3), in the ischaemic control (n = 6), and in the sodium-nitrite infused 
dogs without (NaNO2, n = 7) and with the administration of S-(2-aminoethyl)-isothiourea 
(NaNO2+AEST, n = 6). Compared to the sham-operated group, there were no significant 
changes in iNOS activity in the ischaemic controls, but in the nitrite treated dogs a detectable, 
albeit statistically not significant, increase in enzyme activation could be observed. AEST 
completely inhibited the activation of iNOS, resulted from nitrite administration. Values are 
mean ± SEM. *P < 0.05 compared to the NaNO2 group. 
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